Skip to content
lifestyle.onlygolfnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
RIGEL PHARMACEUTICALS, INC.
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
October 29, 2026
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
October 19, 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 2, 2026
Rigel to Participate in Upcoming September Investor Conferences
September 2, 2026
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
August 14, 2026
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
August 13, 2026
Rigel Reports Second Quarter 2026 Financial Results
August 4, 2026
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
July 28, 2026
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
July 1, 2026
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
June 16, 2026
1
2
Next Page
→